Skip to main content

How antibodies are produced?



Although detailed mechanics of the immune response are beyond the scope of this site, it is useful, in the context of developing a custom antibody, to have an overview of how antibodies are produced by the immune system. 

When an organism’s immune system encounters a foreign molecule (typically a protein) for the first time, specialized cells such as macrophages and dendritic cells capture the molecule and begin breaking it down so that it can present these antigens to B cell lymphocytes.

Once Antigen Presentation to the B cell lymphocytes has occurred, a process known as Somatic Hypermutation allows the B cell to begin coding for a new antibody that will contain a unique Antigen Binding Site in the variable region that is capable of binding specifically to an epitope from the antigen.

Each B cell lymphocyte produces one unique antibody against one unique epitope.

Once antibodies with sufficient specificity to the epitope can be encoded, the B cell begins to release antibodies into the bloodstream. These antibodies then bind specifically with the foreign molecule and allow the immune system to eliminate the molecule from the system.

In some cases, these antibodies can disable pathogens such as viruses directly due to the binding action. In other cases, such as with bacterial pathogens, these antibodies bind to surface proteins on the bacterium’s surface, thereby signaling to the rest of the immune system that the pathogen should be destroyed.

After the foreign molecule has been eliminated, B cells remain in the bloodstream ready to produce antibodies if the antigen is encountered again.

From the perspective of developing a custom antibody. against a protein antigen, the immune system captures the protein, breaks it down into individual epitopes and presents these epitopes to the B cells so that development of antibodies specific to those epitopes can begin. These antibodies can then be collected directly in the serum or by isolating the individual B cells that produce antibody against the epitope of interest. With a full-length protein antigen, there will typically be multiple B cells generating antibodies against multiple epitopes from different regions of the protein.

Comments

Popular posts from this blog

How covid-19 is differ from sars?

COVID-19 , which is caused by the new coronavirus, has been dominating the news lately. However, you may have first become familiar with the term coronavirus during the severe acute respiratory syndrome (SARS) outbreak in 2003. Both COVID-19 and SARS are caused by coronaviruses. The virus that causes SARS is known as SARS-CoV, while the virus that causes COVID-19 is known as SARS-CoV-2. There are also other types of human coronaviruses. Despite their similar name, there are several differences between the coronaviruses that cause COVID-19 and SARS. Keep reading as we explore coronaviruses and how they compare to each other. What is coronavirus? Coronaviruses are a very diverse family of viruses. They have a large host range, which includes humans. However, the greatest amount of coronavirus diversity is seen in batsTrusted Source. Coronaviruses have spiky projections on their surface that look like crowns. Corona means “crown” in Latin — and that’s how this family of viruse...

Development of a new ventilator prototype for the ICU against COVID-19

Development of a new ventilator prototype for the ICU against COVID-19. Credit: UC3M Researchers and technicians from the  Universidad Carlos III de Madrid (UC3M) and the University Hospital Gregorio Marañón (HGUGM)  have designed and developed a new ventilator prototype for Intensive Care Units (ICU) in the fight against the health crisis caused by COVID-19. The assembly of two units has just been completed in order to start animal tests and homologation processes. These ventilators are an indispensable element for patients in intensive care with severe respiratory distress, for whom the mechanical ventilators being developed through other initiatives are not suitable. The project to support the development and manufacturing of these ventilators, which began on 1st April with a crowdfunding campaign organised by the Universidad Carlos III Foundation, achieved its initial funding target (50,000 Euros) in just 24 hours. With this funding, the prototype's creation and testi...

What To Do If You Have A Vaccine Injury

    Currently, 16 vaccines are covered under the Vaccine Injury Compensation Program (VICP) in the United States: influenza, tetanus, pertussis (whooping cough), measles, mumps, rubella, human papillomavirus, meningitis, diphtheria, chicken pox, polio, rotavirus, haemophilus influenzae type b, hepatitis A, hepatitis B, and the pneumonia conjugate vaccine.Some of the more common injuries associated with vaccination are anaphylaxis (a severe allergic reaction), vasovagal syncope (fainting), and SIRVA (shoulder injuries related to vaccine administration).To be eligible for compensation through the VICP, injuries must be deemed severe, defined as symptoms lasting for at least six months or that have caused you to go to a hospital for surgery, or have resulted in death.Vaccine injuries are defined as developing a new illness or aggravating an illness or condition that you already have as a result of receiving a vaccine.Individuals can file VICP claims on behalf of them...